Design Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Design Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for a range of severe genetic conditions characterized by nucleotide repeat expansions. The company leverages its proprietary GeneTAC® (Gene Targeted Chimera) platform to create small molecule therapeutic candidates that are designed to either enhance or suppress the expression of specific disease-causing genes, thus targeting the fundamental biological causes of these disorders. Its clinical pipeline currently includes several programs. For Friedreich's Ataxia, the company is advancing DT-216P2, an optimized GeneTAC molecule, which is actively enrolling patients in a Phase 1/2 multiple-ascending dose clinical trial outside the U.S., with initial data expected in the latter half of 2026. In Myotonic Dystrophy Type 1 (DM1), Design Therapeutics has nominated DT-818 as a development candidate and intends to begin patient dosing in a Phase 1 multiple-ascending dose study in Australia in the first half of 2026, with initial splicing correction data anticipated in 2027. Additionally, DT-168 is undergoing a Phase 2 biomarker trial for Fuchs Endothelial Corneal Dystrophy, with results expected by the second half of 2026. The company also maintains a robust preclinical portfolio exploring therapies for other monogenic diseases driven by repeat expansions, such as Huntington's disease, Fragile X syndrome, and various spinocerebellar ataxias. Established in 2017, Design Therapeutics, Inc. operates from its headquarters in Carlsbad, California.
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why
Design Therapeutics to Participate in Upcoming Investor Conferences
Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results